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Abstract
Activation of the NLRP3 inﬂammasome is crucial for immune defense, but improper and excessive activation causes
inﬂammatory diseases. We previously reported that Pyk2 is essential for NLRP3 inﬂammasome activation. Here we
show that the Src-family kinases (SFKs)-Cbl axis plays a pivotal role in suppressing NLRP3 inﬂammasome activation in
response to stimulation by nigericin or ATP, as assessed using gene knockout and gene knockdown cells, dominant
active/negative mutants, and pharmacological inhibition. We reveal that the phosphorylation of Cbl is regulated by
SFKs, and that phosphorylation of Cbl at Tyr371 suppresses NLRP3 inﬂammasome activation. Mechanistically, Cbl
decreases the level of phosphorylated Pyk2 (p-Pyk2) through ubiquitination-mediated proteasomal degradation and
reduces mitochondrial ROS (mtROS) production by contributing to the maintenance of mitochondrial size. The lower
levels of p-Pyk2 and mtROS dampen NLRP3 inﬂammasome activation. In vivo, inhibition of Cbl with an analgesic drug,
hydrocotarnine, increases inﬂammasome-mediated IL-18 secretion in the colon, and protects mice from dextran
sulphate sodium-induced colitis. Together, our novel ﬁndings provide new insights into the role of the SFK-Cbl axis in
suppressing NLRP3 inﬂammasome activation and identify a novel clinical utility of hydrocortanine for disease
treatment.

Introduction
Inﬂammasomes are cytoplasmic multiprotein complexes that are important for innate immunity. They
comprise various cytosolic pattern recognition receptors,
such as nod-like receptors (NLRPs) and AIM2, along with
the adaptor protein, ASC, and pro-caspase-11. Inﬂammasome assembly triggers an ASC-mediated oligomerization that results in formation of large “speck”
structures2. The ASC specks are required for activation of
caspase-1, which mediates the maturation of interleukin
(IL)-1β and IL-18 and ultimately pyroptotic cell death.
The NLRP3 inﬂammasome can be stimulated by
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associated molecular patterns (e.g., nigericin3 and
ATP4–6). Activation of the NLRP3 inﬂammasome has also
been shown to be critically involved in maintaining epithelial integrity in the colon and attenuating dextran
sulfate sodium (DSS)-induced colitis in mice7,8. However,
excessive activation of the NLRP3 inﬂammasome is
responsible for progression of several inﬂammationassociated diseases, including cryopyrin-associated periodic syndrome9, septic shock10, rheumatoid arthritis11,
Alzheimer’s disease12, and type 2 diabetes13. At present, it
is unclear how the inﬂammasome is regulated to prevent
excessive inﬂammation under normal conditions.
The NLRP3 inﬂammasome can respond to various types
of stimuli, which can activate the inﬂammasome via
kinase activity and mitochondrial reactive oxygen species
(mtROS) production6,14. We previously showed that the
protein tyrosine kinase, Pyk2, critically mediates NLRP3
inﬂammasome activation by directly phosphorylating
ASC at Tyr14615,16. However, it is not known how Pyk2

© The Author(s) 2018
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Ofﬁcial journal of the Cell Death Differentiation Association

Chung et al. Cell Death and Disease (2018)9:1109

itself is regulated. One potential upstream regulator is
Cbl, which has been reported to inhibit mtROS
production17. Many lines of evidence indicate that the
NLRP3 inﬂammasome can be activated by mtROS6, but
there is still a missing link between the regulatory kinases
and mtROS production.
Cbl is encoded by a proto-oncogene and is a RING
ﬁnger E3 ubiquitin ligase18. Cbl negatively regulates many
phosphotyrosine signaling pathways via its N-terminal
tyrosine kinase-binding domain; this allows it to interact
with phosphotyrosine-containing proteins, which it ubiquitinates and thereby targets for proteasomal or lysosomal degradation. Cbl also participates in the maintenance
of mitochondrial function and size. Cbl-knockout (KO)
mice display an increase in whole-body energy expenditure along with mitochondrial hypertrophy in skeletal
muscle19. Although tyrosine phosphorylation and mtROS
are known to regulate NLRP3 inﬂammasome activation,
the potential role of Cbl remains unclear. The E3 ligase
activity of Cbl is regulated through phosphorylation by
Src-family kinases (SFKs)20, and SFKs have been implicated in NLRP3 inﬂammasome activation21,22, thus suggesting a link.
In this study, we show that SFK-Cbl axis plays a role in
suppressing the NLRP3 inﬂammasome. In addition, the
analgesic drug, hydrocotarnine, can block Cbl activity,
therefore enhancing NLRP3 inﬂammasome activation. In
the DSS-induced animal model of colitis, treatment with
hydrocotarnine increased IL-18 secretion and protected
mice from the disease. Together, our results provide
important new insights into the biological processes
responsible for preventing excessive inﬂammation.

Materials and methods
Reagents, antibodies, and plasmids

PMA (phorbol 12-myristate 13-acetate), ATP, nigericin,
CCCP, PP2, dAdT, and MG132 were purchased from
Sigma. MitoSox, H2-DCFDA, TMRE, MitoTracker Green
FM, and Hoechst were purchased from Life Technologies.
MitoTEMPO was purchased from Enzo Life Sciences.
Hydrocotarnine was purchased from Enamine. Anti-Pyk2,
anti-AIM2, and anti-p-Pyk2 were purchased from Cell
Signaling. Anti-Cbl, anti-ASC, anti-caspase-1, anti-IL-1β,
anti-phosphotyrosine, and anti-GAPDH were purchased
from Santa Cruz. Anti-Ly6G, anti-CD45, and anti-CD11b
were purchased from BD Bioscience. Anti-NLRP3 and
anti-F4/80 were purchased from BioLegend and
eBioscience, respectively. Plasmids encoding mutants CBL
(Y371D) and CBL (Y371F) were generated by ligating
ampliﬁed DNA fragments into the NheI/PmeI-treated
pLKO_AS2.neo vector (RNAi Core, Taiwan). The mutant
CBL was constructed using a QuikChange II Site-Directed
Mutagenesis kit (Agilent Technologies), and the following
primers (forward and reverse, respectively): for Cbl
Ofﬁcial journal of the Cell Death Differentiation Association
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Y371D, 5′-CAGGAACAATATGAATTAGACTGTGAG
ATGGGCTCCAC-3′ and 5′-GTGGAGCCCATCTCA
CAGTCTAATTCATATTGTTCCTG-3′; and for Cbl
Y371F, 5′-CAGGAACAATATGAATTATTCTGTGAG
ATGGGCTCCAC-3′ and 5′-GTGGAGCCCATCTCAC
AGAATAATTCATATTGTTCCTG-3′.
Flow cytometric isolation of ASC-mCherry speck-forming
cells

The ASC-mCherry speck-forming cells were isolated by
ﬂow cytometry as described by Sester et al.23. Brieﬂy,
nigericin-treated THP-1-ASC-mCherry cells were gated,
analyzed for their inﬂammasome activation state by pulse
width to pulse area proﬁle (W:A) analysis, and sorted for
the presence/absence of ASC-mCherry specks.
Animal experiments

Mouse experiments were performed under the ethical
approval by the Institutional Animal Care and User
Committee of Chang Gung University, and the methods
were carried out in accordance with the approved
guidelines. C57BL/6 mice were obtained from National
Laboratory Animal Center, Taiwan. Hck/Fgr/Lyn−/− triple KO (TKO) mice were kindly provided by Dr. C. L. Chu
(Graduate Institute of Immunology, College of Medicine,
National Taiwan University, Taipei, Taiwan)24. All mice
were maintained under speciﬁc pathogen-free conditions
and used at 6–9 weeks of age. For lipopolysaccharide
(LPS)-induced endotoxin shock, mice were intraperitoneally treated with 1 or 10 mg/kg of LPS as indicated.
At 24 h after LPS treatment, peripheral blood cells were
collected. Neutrophils (CD45+/Ly6G+) and macrophages
(CD45+/F4/80+) were subjected to antibody staining and
analyzed with a FACSCalibur (Becton Dickinson). To
generate the DSS-induced colitis model, 2.5% DSS
(molecular weight, 36 000–50 000; MP Biomedicals) was
given to mice via the drinking water. To evaluate the
protective effect of Cbl on DSS-induced colitis, mice were
dosed with 10 mg/kg of hydrocotarnine by intraperitoneal
injection daily from day 0 to day 9. Treatment with 2.5%
DSS began on day 1 and ended on day 7. Body weight was
assessed daily. Mice were sacriﬁced at day 10. Colon
length measurement and colon organ culture were performed. For histopathological analysis, colons were ﬁxed,
embedded, sectioned, and stained with hematoxylin and
eosin. The histopathology was scored with respect to
inﬂammation, epithelial defects, and crypt atrophy, as
previously described25.
Cell culture

Bone marrow cells were collected from the tibias and
femurs of wild-type (WT) and TKO C57BL/6 mice by
ﬂushing with cold phosphate-buffered saline (PBS) using a
25-G needle, and mouse bone marrow-derived
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macrophages (BMDMs) were generated and cultured in
Dulbecco’s modiﬁed Eagle medium supplemented with
10% fetal calf serum and 10 ng/ml macrophage colonystimulating factor (PeproTech) for 8 days. The THP-1
(human leukemia monocytic) cell line was purchased
from the Biosource Collection and Research Center
(Taiwan) and maintained in RPMI as described
previously26. The ASC-mCherry-expressing THP-1 cells
were kindly provided by Dr. M. Z. Lai (Institute of
Molecular Biology, Academia Sinica, Taipei, Taiwan)27.
For macrophage differentiation, THP-1 cells were stimulated with 200 nM PMA for 16 h. For inﬂammasome
activation, the cells were treated with 10 μM nigericin for
0.5 or 1 h as indicated, with 5 mM ATP for 4 h, with 200
μg/ml monosodium urate (MSU) for 4 h, or with 2 μg/ml
poly(dA:dT) for 4 h. For inhibition of signaling or caspase
activity, the cells were pretreated with PP2 (10 μM), ZVAD-FMK (20 μM), MitoTEMPO (1 μM), MG132
(3 μM), or hydrocotarnine (10 μM) for 1 h, and then
subjected to inﬂammasome stimulation. The Cbl-KO
HEK293T cell line was generated using the CRISPR/
Cas9 system with dual small guide RNAs targeting Cbl
(CTCGGCTCGACTGCGAGCGA and GTCCACCG
TCCCCGGCGGGT). For the reconstitution of NLRP3
inﬂammasomes, WT and Cbl-KO HEK293T cells were
co-transfected with pLKO_AS2-Flag-NLRP3, pLKO_AS2ASC-Flag, pLKO.1-IL-1β, or pCMV6-Entry-Casp-1 using
Lipofectamine 2000 (Invitrogen) as previously described16. The cells were then incubated for 48 h and analyzed as described for the HEK293T cells. For Cbl
reconstitution, Cbl-KO HEK293T cells were transduced
with lentiviral vectors encoding mutant Cbl (Y371D or
Y371F) and selected with puromycin.
RNA interference

The double-stranded RNA duplexes were purchased
from Dharmacon and transfected into cells using Lipofectamine 2000, as previously described28. For efﬁcient
knockdown, the cells were incubated for 2 days. The
reagent used to target Cbl included three 19-bp RNA
duplexes: 5′-GACAAUCCCUCACAAUAAA-3′, 5′-UAG
CCCACCUUAUAUCUUA-3′, and 5′-GGAGACACAU
UUCGGAUUA-3′.
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samples were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose
membranes (Amersham). The membranes were incubated with the indicated primary antibodies, and then
with an horseradish peroxidase (HRP)-conjugated secondary antibody. The immunoreactive bands were
detected using TOOLS Extreme ECL-HRP Substrate
(BIOTOOLS CO., LTD. Taiwan). Immunoblot images
were quantiﬁed with the ImageJ software.
Immunoprecipitation

Cells were lysed in RIPA buffer with a protease inhibitor
cocktail, and cell extracts (1 mg) were immunoprecipitated with anti-Pyk2 antibodies (1 μg) for 24 h. The corresponding rabbit IgGs (Millipore) were used as the
control antibodies. The bound samples were precipitated
with PureProteome Protein G Magnetic Beads (Millipore)
for 1 h at 4 °C, and the immunoprecipitated products were
collected for immunoblot analysis.
ASC oligomerization assay

THP-1 cells were lysed in buffer A (20 mM
HEPES-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM
EDTA, 1 mM EGTA, and 320 mM sucrose) supplemented
with a protease inhibitor cocktail. Nuclei and unlysed cells
were removed by centrifugation through 5 μm UltrafreeCL centrifugal ﬁlters (Millipore). The ﬁltrate was diluted
with an equal volume of CHAPS buffer (20 mM HEPESKOH, pH 7.5, 5 mM MgCl2, 0.5 mM EGTA, and 0.1%
CHAPS) supplemented with a protease inhibitor cocktail,
and centrifuged to obtain the insoluble pelleted fraction.
The pellets were resuspended in CHAPS buffer and then
subjected to crosslinking using 2 mM disuccinimidyl
suberate for 30 min. The protein samples were resolved by
12% SDS-PAGE, and the level of ASC was analyzed. ASC
speck formation was analyzed in mouse BMDMs and
ASC-mCherry-expressing THP-1 cells. ASC speck images
were acquired under ﬂuorescence microscopy (Olympus).
For quantiﬁcation, the ASC specks were counted with an
IN Cell Analyzer (GE Healthcare) and normalized with
respect to the number of nuclei, which were stained with
4′,6-diamidino-2-phenylindole.
Enzyme-linked immunosorbent assay

Immunoblot analysis

Cells were lysed in RIPA buffer (50 mM Tris-Cl, pH 7.5,
150 mM NaCl, 10 mM MgCl2, 1 mM EDTA, and 1% Igepal CA-630) with a protease inhibitor cocktail (4.76 μg/ml
leupeptin, 3.25 μg/ml aprotinin, 0.69 μg/ml pepstatin, and
1 mM phenylmethylsulfonyl ﬂuoride) on ice for 30 min.
For assessment of IL-1β secretion and caspase-1 activation, culture supernatants were collected, mixed with a
1/10 volume of 100% (wt/vol) trichloroacetic acid, and
incubated for 10 min at 4 °C. The precipitated protein
Ofﬁcial journal of the Cell Death Differentiation Association

Cell culture supernatants and mouse sera were assayed
for human IL-1β (eBioscience), human IL-18 (R&D Systems), and mouse IL-1β (eBioscience), respectively. Colon
organ culture supernatants were assayed for mouse IL-18
(R&D Systems).
Mitochondrial and cellular ROS measurements

Mitochondrial and cellular ROS were measured using
MitoSox Red and H2-DCFDA (Life Technologies),
respectively. The cells were incubated with 5 μM MitoSox
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Red or 10 μM H2-DCFDA at 37 °C for 20 min, and then
analyzed by ﬂow cytometry.
Confocal microscopy

Cells were treated with MitoTracker Green FM (200
nM) and Hoechst (5 μg/ml) for 30 min. To measure the
cellular distribution of mitochondria, images were
obtained with a confocal laser scanning microscope (Carl
Zeiss, LSM780) and processed with the ZEN microscopic
software (Carl Zeiss).
Transmission electron microscopy

The cells were ﬁxed in 3% glutaraldehyde and 2% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.4) for 2 h
at 4 °C. The cells were then postﬁxed in 1% osmium
tetroxide (pH 7.4), dehydrated in a graded ethanol series,
and embedded in EPON-812 (Nacalai Tesque, Japan).
Thin sections (80 nm) were cut, stained with uranyl
acetate and lead citrate, and examined on an H-7500 EM
transmission electron microscope (Hitachi). Micrographs
(×9000−×12 000) were analyzed with the ImageJ software
(version 1.51s), which was used to manually trace the
mitochondrial outer membrane area and cytoplasm area
for calculation of the number, average size (μm2), and
volume density (% of cytoplasm) of mitochondria. Eleven
and 16 randomly selected cells were examined from the
WT and Cbl-KO groups, respectively.
Statistical analysis

All statistical analyses were performed using the SPSS
13.0 statistical software package (SPSS, Inc.). Data from
in vitro experiments and tumor growth in the mouse
model were analyzed with the Student’s t test. Differences
were considered signiﬁcant at P < 0.05.

Results
Cbl inhibits NLRP3 inﬂammasome activation

We previously showed that p-Pyk2 enables NLRP3
inﬂammasome activation through the direct phosphorylation of ASC at Tyr14616. However, much less is known
about the degradation of p-Pyk2, which leads to suppression of NLRP3 inﬂammasome activity. Cbl is a
phosphotyrosine-interacting protein that targets proteins
with its ubiquitin ligase activity to route them for proteasomal degradation29. Here we examined the role of Cbl
in suppressing NLRP3 inﬂammasome activation. During
formation of the NLRP3 inﬂammasome complex, ASC
molecules form a speck and oligomerize to recruit procaspase-1 prior to the activation of caspase-1. To quantify
inﬂammasome formation in ASC speck-positive and
-negative cells after stimulation, we carried out
time-of-ﬂight inﬂammasome evaluation analysis23. In
ASC-mCherry-expressing THP-1 cells treated with the
NLRP3 agonist, nigericin, the percentage of ASC
Ofﬁcial journal of the Cell Death Differentiation Association
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speck-containing cells was increased to 35.4% compared
with the 5.7% seen in untreated cells (Fig. 1a, top).
Notably, the level of Cbl protein was 0.6-fold in ASC
speck-containing cells relative to ASC speck-negative cells
(Fig. 1a, bottom). This suggested that there was a higher
Cbl protein level in cells that failed to efﬁciently form ASC
specks. We further examined whether Cbl depletion
affects ASC oligomerization, and found that nigericin
induced more ASC oligomers in THP-1 cells treated with
a Cbl-speciﬁc small interfering RNA (siRNA) compared to
those treated with control siRNA (Fig. 1b). To evaluate
whether Cbl is involved in regulating the NLRP3 inﬂammasome, we analyzed changes in caspase-1 activation and
IL-1β maturation in cells treated with nigericin or ATP
(both agonists of the NLRP3 inﬂammasome). The levels of
mature IL-1β p17 and active caspase-1 (as assessed by the
level of caspase-1 p10) were increased in both Cblknockdown THP-1 cells (Fig. 1c) and NLRP3
inﬂammasome-reconstituted Cbl-KO HEK293T cells
achieved by CRISPR/Cas9 technology (Fig. 1d). However,
Cbl knockdown in THP-1 cells did not change the
amounts of poly(dAdT)-induced mature IL-1β, cleaved
caspase-1, or ASC oligomers (Supplementary Figure S1).
These results suggest that the ligase activity of Cbl speciﬁcally suppresses the NLRP3 inﬂammasome, but not the
AIM2 inﬂammasome.
Phosphorylation of Cbl at Y371 is required to inhibit
NLRP3 inﬂammasome activation

The ligase activity of Cbl is regulated by a conformational change that is triggered by the phosphorylation of
Cbl at Tyr37129,30. Thus, we hypothesized that the
phosphorylation could govern the ability of Cbl to
suppress NLRP3 inﬂammasome activation. We evaluated the production of mature IL-1β and cleaved,
activated caspase-1 in NLRP3 inﬂammasomereconstituted Cbl-KO HEK293T cells stably expressing
constructs encoding constitutively active Cbl (Cbl
Y371D) or dominant-negative Cbl (Cbl Y371F) in the
presence and absence of nigericin stimulation31. As
shown in Fig. 1e, the ability of nigericin stimulation to
induce mature IL-1β and cleaved caspase-1 was dramatically repressed in cells expressing constitutively
active Cbl (Y371D), but not in the cells expressing
dominant-negative Cbl (Y371F). These results strongly
support the notion that Tyr371 phosphorylation and
ligase activity of Cbl contribute to regulation of the
NLRP3 inﬂammasome.
Cbl inhibits Pyk2 signaling via ubiquitination-mediated
proteasomal degradation

Since Pyk2 is critical for NLRP3 inﬂammasome
activation16 and has been detected in the
Cbl-interactome32,33, we speculated that Cbl may
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Fig. 1 Phosphorylation of Cbl at Y371 is required to suppress the NLRP3 inﬂammasome. a ASC-mCherry-expressing THP-1-derived
macrophages were treated with nigericin for 1 h, ASC speck-containing cells were isolated by ﬂow cytometry (low and high ASC-W:ASC-A proﬁles
were taken as indicating ASC speck-positive and -negative cells, respectively), and immunoblotting was performed using anti-Cbl and anti-GAPDH
antibodies. b Analysis of ASC oligomerization in THP-1-derived macrophages that were treated with Cbl siRNA or negative control siRNA (C) and
stimulated with nigericin for 1 h. c THP-1-derived macrophages were transfected with Cbl siRNA or negative control siRNA (C) and treated with
nigericin for 1 h or ATP for 4 h, and culture supernatants (SN) and cell lysates (CL) were immunoblotted with antibodies that recognize Cbl, GAPDH,
and NLRP3 inﬂammasome molecules. d NLRP3 inﬂammasome activation was analyzed in reconstituted WT and Cbl-KO HEK293T cells that were cotransfected with vectors encoding Flag-NLRP3, ASC-Flag, IL-1β, or caspase-1 for 48 h, treated with nigericin for 5 h, separated into SN and CL fractions,
and immunoblotted with antibodies that recognize Cbl, GAPDH, and NLRP3 inﬂammasome molecules. e Cbl-KO HEK293T cells stably expressing
empty vector (EV) or mutant CBL (Y371D or Y371F) were treated with nigericin for 5 h, and SN and CL were immunoblotted with antibodies that
recognize Cbl, GAPDH, and NLRP3 inﬂammasome molecules. The western blot is a representative of three independent experiments. procasp-1, p45
precursor of caspase-1; cleaved Casp-1, p20 and p10 active caspase-1 subunits; IL-1β p17, secreted mature IL-1β; and pro-IL-1β, p31 precursor of IL-1β

suppress the NLRP3 inﬂammasome through negative
regulation of Pyk2. To address this possibility, we ﬁrst
examined the global pattern of tyrosine-phosphorylated
proteins during NLRP3 inﬂammasome activation. As
Ofﬁcial journal of the Cell Death Differentiation Association

shown in Fig. 2a, stimulation with nigericin signiﬁcantly
decreased the global level of tyrosine-phosphorylated
proteins by 0.4-fold. Treatment with ATP showed similar
results (Supplementary Figure S2). In addition, treatment
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Fig. 2 Cbl inhibits Pyk2 signaling via ubiquitination-mediated proteasomal degradation. a THP-1-derived macrophages were left untreated
(UT) or treated with nigericin for 1 h, and tyrosine-phosphorylated proteins (p-Tyr) were detected by immunoblotting with anti-p-Tyr antibodies.
b THP-1-derived macrophages were treated with 0.1, 1, or 10 μM hydrocotarnine for 1 h and immunoblotted with anti-p-Tyr and anti-GAPDH. c THP1-derived macrophages were pretreated with 10 μM hydrocotarnine for 1 h, treated with nigericin for 1 h, and subjected to immunoblotting with
anti-p-Pyk2, anti-Pyk2, and anti-GAPDH antibodies. d THP-1-derived macrophages were pretreated with 10 μM hydrocotarnine for 1 h, and cell lysates
were subjected to immunoprecipitation (IP) using anti-Pyk2 followed by immunoblotting with anti-ubiquitin (Ub) and anti-Pyk2 antibodies. e THP-1derived macrophages were pretreated with MG132 for 1 h, treated with nigericin for 1 h, and subjected to immunoblotting with anti-p-Pyk2, antiPyk2, and anti-GAPDH antibodies. The western blot is representative of three independent experiments. f, g THP-1-derived macrophages were
pretreated with 10 μM hydrocotarnine for 1 h and then treated with nigericin for 1 h, and supernatants were subjected to IL-1β (f) and IL-18 (g) ELISA.
*P < 0.05; **P < 0.01. All results are presented as the mean ± SD of three independent experiments, and were analyzed with the Student’s t test

with the Cbl-speciﬁc inhibitor, hydrocotarnine (CRIN-2,
patent number: WO2011160016A2), dose-dependently
increased the global level of tyrosine-phosphorylated
proteins (Fig. 2b) and induced p-Pyk2 (Fig. 2c) in
THP-1 cells. Notably, hydrocotarnine treatment
attenuated the reduction of p-Pyk2 seen following NLRP3
activation (Fig. 2c) and decreased the ubiquitination of
Pyk2 (Fig. 2d). Thus, Cbl contributes to negative
regulation of p-Pyk2 through ubiquitin-mediated proteasomal degradation. This possibility was supported by our
observation that p-Pyk2 is increased in THP-1 cells
treated with the proteasome inhibitor, MG132 (Fig. 2e).
Moreover, the secretion of IL-1β and IL-18 was signiﬁcantly
elevated
in
hydrocotarnine-pretreated
THP-1 cells compared to control cells (Fig. 2f,g and
Supplementary Figure S3). Taken together, our results
suggest that Cbl likely suppresses the NLRP3 inﬂammasome due to negative regulation of Pyk2.
Ofﬁcial journal of the Cell Death Differentiation Association

Cbl maintains mitochondrial size and reduces ROS
production

In addition to Pyk2 signaling, NLRP3 inﬂammasome
activation is regulated by mitochondrial dysfunction and
downstream mtROS production34. In Cbl-deﬁcient
mice, the mitochondrial size is reportedly enlarged in
muscle tissues19. To determine if the same might be true
in our in vitro system, we used electron microscopy to
analyze the structure of mitochondria in Cbl-KO
HEK293T cells. We found that the average size of
mitochondria was increased (Fig. 3a, b, left), but the
average number of mitochondria per cell was decreased
in Cbl-KO HEK293T cells compared with WT
HEK293T cells (Fig. 3b, middle). There was no difference between Cbl-KO and WT cells with respect to
mitochondrial density (Fig. 3b, right) or the cellular
distribution of mitochondria (Fig. 3c). Next, we examined whether Cbl might also affect mitochondrial health.
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Fig. 3 Cbl maintains mitochondrial size and reduces mtROS production. a Representative electron micrographs of WT and Cbl-KO HEK293T cells
treated with nigericin for 5 h. Magniﬁcation, ×75 000; scale bar, 100 nm. b Quantiﬁcation of the average size (μm2), number and volume density (% of
cytoplasm) of mitochondria from WT and Cbl-KO HEK293T cells treated with nigericin for 5 h. Eleven and 16 cells were randomly examined from the
WT and Cbl-KO cell groups, respectively. c Representative confocal images of the cellular distribution of mitochondria in WT and Cbl-KO
HEK293T cells treated with nigericin for 5 h. Mitochondria are shown in green, while nuclei are blue. Scale bar, 5 μm. d Productions of mitochondria
and cellular ROS by WT and Cbl-KO HEK293T cells treated with nigericin for 0.5 or 1 h were measured using MitoSOX and H2-DCFDA, respectively.
*P < 0.05; **P < 0.01. All results are presented as the mean ± SD of three independent experiments, and were analyzed with the Student’s t test. e WT
or Cbl-KO HEK293T cells were pretreated with MitoTEMPO for 1 h and treated with nigericin for 5 h, and culture supernatants (SN) and cell lysates (CL)
were subjected to immunoblotting with antibodies that recognize Cbl, GAPDH, and NLRP3 inﬂammasome molecules. The western blot is a
representative of three independent experiments. procasp-1, p45 precursor of caspase-1; cleaved Casp-1, p20 and p10 active caspase-1 subunits;
IL-1β p17, secreted mature IL-1β; and pro-IL-1β, p31 precursor of IL-1β

In response to the NLRP3 activator, nigericin, both CblKO and WT cells exhibited increased production of
mtROS and cellular ROS (Fig. 3d). Notably, a signiﬁcantly higher induction of mtROS production was
observed in Cbl-KO cells compared with WT cells
(Fig. 3d, left). Consistent with this increase in mtROS
production, higher levels of mature IL-1β and cleaved
caspase-1 were observed in Cbl-KO cells compared with
WT cells in response to NLRP3 inﬂammasome activation, and these effects were partially inhibited by pretreatment with the mtROS scavenger, MitoTEMPO
(Fig. 3e). These data suggested that Cbl is required to
Ofﬁcial journal of the Cell Death Differentiation Association

maintain mitochondrial size and function, which critically contribute to NLRP3 inﬂammasome activation by
modulating mtROS production.
SFK-mediated Cbl phosphorylation inhibits NLRP3
inﬂammasome activation

As ubiquitination of Cbl requires the prior phosphorylation of Tyr371 by SFKs20 and our present results
indicate that Cbl critically suppresses the NLRP3
inﬂammasome, we examined whether regulator SFKs, as
upstream regulators of Cbl, might suppress the NLPR3
inﬂammasome. As shown in Fig. 4a, the levels of Cbl
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Fig. 4 Cbl activity is regulated by SFKs. a Cell lysates obtained from bone marrow-derived macrophages (BMDMs) of WT C57BL/6 and TKO
mice were subjected to IP using anti-Cbl and immunoblotted with anti-phosphotyrosine, anti-Cbl, anti-p-Pyk2, anti-Pyk2, and anti-GAPDH antibodies.
b, c THP-1-derived macrophages were pretreated with PP2 or DMSO for 1 h and treated with nigericin for 1 h, and cell lysates were subjected to IP
and immunoblotting with the indicated antibodies. The western blot is representative of three independent experiments. d THP-1-derived
macrophages were pretreated with PP2 or DMSO for 1 h and treated with nigericin for 15 min, and productions of mitochondria and cellular ROS
were measured using MitoSOX and H2-DCFDA, respectively. e Cbl-KO HEK293T cells stably expressing empty vector (EV) or mutant CBL (Y371D or
Y371F) were treated with nigericin for 1 h and subjected to measurement of mitochondria and cellular ROS. *P < 0.05; **P < 0.01. All results are
presented as the mean ± SD of three independent experiments, and were analyzed with the Student’s t test

phosphorylation were decreased by 0.1-fold in BMDMs
from TKO mice deﬁcient in the three SFKs, Hck, Fgr, and
Lyn. In contrast, the level of Pyk2 phosphorylation was
markedly increased by 3.1-fold in BMDMs from TKO
mice. Treatment of THP-1 cells with the SFK-speciﬁc
inhibitor, PP2, reduced Cbl phosphorylation in the
absence and presence of nigericin by 0.6- and 0.7-fold,
respectively, compared to the dimethyl sulfoxide control
(Fig. 4b). Moreover, PP2 treatment induced Pyk2 phosphorylation from 1.0- to 1.4-fold and from 0.7- to 1.0-fold
in the untreated and nigericin-treated groups, respectively
(Fig. 4c). We also examined whether mtROS production
might be regulated by SFKs in response to NLRP3
inﬂammasome activation. As shown in Fig. 4d, the level of
mtROS induced by nigericin was higher in PP2-pretreated
THP-1 cells, but there was no change in cellular ROS
Ofﬁcial journal of the Cell Death Differentiation Association

production. As our data indicated that reduced mtROS
production and phosphorylation of Cbl at Y371 are
required for the Cbl-mediated negative regulation of
NLRP3 inﬂammasome activation, we further investigated
whether Tyr371 phosphorylation of Cbl is required for
mtROS production. As shown in Fig. 4e, the nigericintriggered induction of mtROS was repressed in
HEK293T cells expressing constitutively active Cbl
(Y371D) but not dominant-negative Cbl (Y371F), whereas
these cells did not differ in their production of cellular
ROS. These results reveal that Pyk2 activity and mtROS
production are all regulated by SFKs and the phosphorylation of Cbl at Y371 may participate in
Cbl-mediated mtROS production.
We further tested the effect of SFK deﬁciency and/or
inhibition on activation of the NLRP3 inﬂammasome. We
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found that the induction of IL-1β secretion by nigericin or
ATP was increased in BMDMs from TKO mice (Fig. 5a)
and PP2-pretreated THP-1 cells (Fig. 5b), suggesting that
SFKs may suppress nigericin- or ATP-induced NLRP3
inﬂammasome activation. Consistent with this notion, the
levels of mature IL-1β p17 and active caspase-1 p10
induced by nigericin or ATP were increased in
PP2-pretreated THP-1 cells (Fig. 5c). After ATP stimulation, the percentage of ASC speck-containing cells was
increased from 44.4% in BMDMs from WT mice to 72.6%
in those from TKO mice (Fig. 5d, left). In ASC-mCherryexpressing THP-1 cells, PP2 treatment increased the
proportion of nigericin-induced ASC speck-containing
cells from 30.1 to 37.7% (Fig. 5d, right). The nigericininduced oligomerization of ASC in THP-1 cells was also
further increased by PP2 treatment (Fig. 5e). The abovedescribed SFK-Cbl-mediated inﬂammasome regulation
was not detected during poly(dAdT)-induced AIM2
inﬂammasome activation in BMDMs or THP-1 cells, nor
in PP2-treated THP-1 cells or BMDMs from WT or TKO
mice (Supplementary Figure S4). These ﬁndings indicate
that the SFK-mediated phosphorylation of Cbl is involved
in suppressing the NLRP3 inﬂammasome but not the
AIM2 inﬂammasome.
To determine the physiological signiﬁcance of SFKs in
NLRP3 inﬂammasome suppression in vivo, we tested the
effect of SFK deﬁciency in the mouse model of
LPS-induced septic shock. LPS challenge yielded a much
higher mortality rate in TKO mice compared to WT mice
(Supplementary Figure S5a). The percentage of
neutrophils but not macrophages was higher in peripheral
blood from TKO mice compared to WT mice
(Supplementary Figure S5b). Importantly, serum IL-1β
production was signiﬁcantly elevated in TKO mice compared to WT mice after the peritoneal injection of LPS
(Supplementary Figure S5c). These results indicated that
SFKs protect mice from endotoxic shock by suppressing
the LPS-induced activation of the NLRP3 inﬂammasome
in vivo.
Inhibition of Cbl attenuates acute ulcerative colitis

Activation of the NLRP3 inﬂammasome has been
shown to critically maintain epithelial integrity in the
colon and attenuate DSS-induced colitis in mice7,8.
Therefore, we assessed whether decreasing negative regulation of the NLRP3 inﬂammasome activation could
attenuate colitis in an animal model by treating DSSexposed mice with the Cbl inhibitor, hydrocotarnine
(Fig. 6a). Indeed, hydrocotarnine signiﬁcantly attenuated
the weight loss of mice with DSS-induced colitis compared to PBS-treated control mice (Fig. 6b).
To further assess the disease status, we examined the
colon length, which can be used as an indicator of disease
severity. Indeed, the colons of hydrocotarnine-treated
Ofﬁcial journal of the Cell Death Differentiation Association
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mice appeared to be signiﬁcantly longer than those of
PBS-treated control mice (~6.1 vs. ~5.5 cm) (Fig. 6c). The
histopathology score, which was determined by combining the individual scores of inﬂammation, epithelial
defects,
and
crypt
atrophy25,
indicated
that
hydrocotarnine-treated mice presented with signiﬁcantly
lower scores than PBS-treated control mice (Fig. 6d, e).
Since IL-18 production downstream of the NLRP3
inﬂammasome is critically involved in protection against
colitis and colorectal tumorigenesis35,36, we further
determine IL-18 production in colon. The level of IL-18
was also signiﬁcantly enhanced in colon organ cultures
from hydrocotarnine-treated mice compared with control
mice (Fig. 6f), suggesting that NLRP3 inﬂammasome
activation was enhanced in hydrocotarnine-treated mice.
This result was consistent with the apparent ability of Cbl
to inhibit NLRP3 inﬂammasome-mediated processing of
IL-18.

Discussion
Activation of the NLRP3 inﬂammasome is critical for
immune defense, but improper and excessive activation
can lead to inﬂammatory disease. Much remains to be
learned about mechanisms that restrain inﬂammasome
activation under normal conditions. Based on our present
results, we propose a model for regulation of the NLRP3
inﬂammation by the SFK-Cbl axis (Fig. 7). Importantly,
inhibition of Cbl with the pharmacological inhibitor,
hydrocotarnine, enhances NLRP3 inﬂammasome activation and protects mice from DSS-induced colitis. Together, these novel results demonstrate a new mechanistic
role for the SFK-Cbl axis in negatively regulating the
NLRP3 inﬂammasome and reveal the availability of a
novel treatment for colitis.
Recently, studies using pharmacological inhibitors have
suggested that SFKs promote NLRP3-dependent IL-1β
secretion in response to MSU37, malarial hemozoin21,
inﬂuenza A virus38, and trichothecene mycotoxins22.
Based on secretome analysis of MSU-stimulated macrophages, Nyman et al. reported that Src/Pyk2/PI3 kinase
activity is required for the secretion of IL-1β and IL-1837.
However, these studies did not provide direct evidence for
the ability of SFKs to mediate inﬂammasome activation
and caspase-1 cleavage. Here we conﬁrm that SFKs promote MUS-induced IL-1β secretion in our system (Supplementary Figure S6), but our gene KO and
pharmacological inhibition studies show that SFKs can
also exert an opposing function by suppressing ATP- or
nigericin-stimulated NLRP3 inﬂammasome activation.
We found that SFK deﬁciency (in TKO mice) enhances
the induction of IL-1β secretion and ASC speck formation
in BMDMs and increases the LPS-induced mortality rate
in vivo. The PP2-mediated inhibition of SFKs signiﬁcantly
increases caspase-1 cleavage, IL-1β maturation, ASC
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Fig. 5 SFKs inhibit the NLRP3 inﬂammasome. BMDMs from WT C57BL/6 and TKO mice (a) or PP2-preteated THP-1 derived macrophages (b) were
treated with nigericin for 1 h or ATP for 4 h and supernatants were subjected to IL-1β ELISA. c THP-1-derived macrophages were pretreated with or
without PP2 for 1 h and treated with nigericin for 1 h or ATP for 4 h, and SN or CL were subjected to immunoblotting with antibodies that recognize
GAPDH and NLRP3 inﬂammasome molecules. d Left panel: BMDMs from WT and TKO mice were treated with ATP for 4 h and ASC speck formation
was visualized by immunostaining with an anti-ASC antibody. Right panel: PMA-differentiated ASC-mCherry-expressing THP-1 cells were pretreated
with PP2, and then treated with nigericin for 1 h. ASC is shown in green (left panel) or red (right panel), while nuclei are shown in blue. Scale bars, 20
μm. The bottom panels present the percentages of cells with ASC specks, as determined by an IN Cell Analyzer. e Analysis of ASC oligomerization in
THP-1-derived macrophages pretreated with PP2 and stimulated with nigericin for 1 h. procasp-1, p45 precursor of caspase-1; cleaved Casp-1, p20
and p10 active caspase-1 subunits; IL-1β p17, secreted mature IL-1β; and pro-IL-1β, p31 precursor of IL-1β. *P < 0.05; **P < 0.01. These data are
representative of three independent experiments
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Fig. 6 Cbl inhibitor treatment attenuates acute ulcerative colitis in a mouse model. a Schematic presentation of the DSS-induced mouse
model of colitis. Mice were injected intraperitoneally with hydrocotarnine for 10 consecutive days (day 0 to day 9) and exposed to DSS or PBS
(control) via their drinking water for 7 consecutive days (day 1 to day 7) to induce colitis. All mice were sacriﬁced on day 10; n = 5 mice/group.
b Percent weight change was monitored daily. c Colon length. d Representative photomicrographs of H&E-stained colon sections; scale bars, 100 μm.
e Histological scores were examined in hydrocotarnine-treated and PBS control mice on day 10. f ELISA of IL-18 from colon organ cultures obtained
from hydrocotarnine-treated and PBS control mice on day 10. *P < 0.05

speck formation, and ASC oligomerization in THP-1derived macrophages. Consistent with our ﬁndings, a
previous study showed that deletion of the SFK, Lyn, can
aggravate LPS-induced lung inﬂammation39. Importantly,
we found that downregulation of SFK activity by gene KO
or PP2 treatment was associated with a decrease in
phosphorylated Cbl (p-Cbl) but increased levels of p-Pyk2
and mtROS, which are important mediators for NLRP3
inﬂammasome activation. Thus, SFKs may exert opposing
functions in response to different stimuli for NLRP3
inﬂammasome activation. ATP activates the NLRP3
inﬂammasome through its receptor P2X7R, and both
ATP- and nigericin-induced NLRP3 inﬂammasome activation requires potassium efﬂux40. As indicated in Fig. 7,
the Src/Cbl/Pyk2 axis is required for regulation of the
NLRP3 inﬂammasome in response to ATP and nigericin.
On the other hand, MSU, which enters cells through
phagocytosis, activates NLRP3 through Src/Pyk2/PI3
Ofﬁcial journal of the Cell Death Differentiation Association

kinase37. We speculate that this discrepancy may result
from the different downstream signal pathways that are
involved in inﬂammasome activation in response to different types of stimuli.
Phosphorylation of Pyk2 is important for signal transduction41,42. However, the mechanism responsible for
suppressing Pyk2 signaling remained unclear. Here we
show that p-Pyk2 is downregulated by Cbl through ubiquitination and proteasome-dependent degradation. A
recent study reported that the Cbl family member, Cbl-b,
is involved in the mono-ubiquitination-mediated trypsininduced degradation of Pyk243. Here we show that the loss
of the Cbl upstream activators, SFKs, is associated with a
high level of p-Pyk2 and a correspondingly low level of pCbl, indicating that the SFK-Cbl axis is a negative regulator of Pyk2 signaling. In line with our previous report
that Pyk2 is critical for NLRP3 inﬂammasome activation16, we found that gene KO or pharmacological
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Fig. 7 Model for SFK-Cbl axis-dependent negative regulation of
the NLRP3 inﬂammasome. Based on our results, we propose that
phosphorylation of Cbl is regulated by Src-family kinases, and that
phosphorylation of Cbl at Tyr371 contributes to suppression of the
NLRP3 inﬂammasome. The suppressive function of Cbl is dependent
on its ability to downregulate p-Pyk2 via ubiquitination and
proteasomal degradation, which reduces the Pyk2-mediated
phosphorylation of ASC at Tyr146. Meanwhile, Cbl also reduces mtROS
by maintaining homeostasis (appropriate size) of mitochondria. Both
Tyr146-phosphorylated ASC and mtROS are negatively regulated by
Cbl and are essential for NLRP3 inﬂammasome activation. Finally, the
ability of Cbl to suppress NLRP3 inﬂammasome activation can be
abrogated by the Cbl inhibitor, hydrocotarnine

inhibition of SFKs or Cbl both increases the level of pPyk2 and enhances NLRP3 inﬂammasome activation.
Consistent with the ability of Cbl to suppress the NLRP3
inﬂammasome, depletion of Cbl-b reportedly increased
inﬂammasome activation in response to infection by
Candida albicans44. Together, these ﬁndings indicate that
the SFK-Cbl axis suppresses the NLRP3 inﬂammasome
through downregulation of Pyk2 signaling.
Enlarged mitochondria were previously observed in
muscle cells from Cbl-deﬁcient mice19. In agreement with
the previous ﬁnding, we found that Cbl deﬁciency causes
the size of mitochondria in HEK293T cells to increase.
The mitochondrion is a dynamic organelle whose size is
regulated by mitochondrial fusion/ﬁssion; these processes
are critical for the elimination of damaged mitochondria
under environmental stress45. Dysfunction of mitochondrial fusion/ﬁssion increases the presence of damaged
Ofﬁcial journal of the Cell Death Differentiation Association
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mitochondria, which then become a major source of ROS.
Several lines of evidence support the idea that mtROS is a
direct activator of the NLRP3 inﬂammasome6,46. Consistent with this notion, we observed that nigericin stimulation increases mtROS production and NLRP3
inﬂammasome activation in Cbl-KO HEK293T cells,
which harbor enlarged mitochondria. This observation
agrees with a previous study showing that Cbl knockdown
increases ROS production in T-cell lymphoma cells17.
Mitochondrial ﬁssion is mediated by Dyn247, and Dyn2
depletion leads to enlargement of mitochondrial size48.
Dyn2 also contributes to the Cbl-regulated degradation of
the epidermal growth factor receptor (EGFR)49, and a
Cbl-regulated interaction between Dyn2 and Cblinteracting protein of 85K (CIN85) is important for
EGFR endocytosis50. It has been speculated that Cbl may
regulate mitochondrial size through the Dyn2-CIN85
complex. Here we provide new insights into the role of
Cbl-regulated mitochondrial size and mtROS production
in inhibition of the NLRP3 inﬂammasome.
Activation of the NLRP3 inﬂammasome is critical for
the ability of an organism to ﬁght antimicrobial infection51–53 and protect against some inﬂammation-related
diseases, such as carcinogenesis during DSS-induced
colitis7,8,36. The NLRP3 inﬂammasome is also involved
in the ability of chemotherapeutics to act against
tumors28,54. Here we show for the ﬁrst time that the SFKCbl axis is involved in negatively regulating the NLRP3
inﬂammasome. Importantly, we show that inhibiting Cbl
with the small molecule, hydrocotarnine, can increase the
expression of p-Pyk2, which is essential for NLRP3
inﬂammasome activation by directly phosphorylating
ASC16. Consistently, hydrocotarnine can enhance IL-18
secretion in response to NLRP3 inﬂammasome activation
in vitro and enhance IL-18 secretion in vivo in the colon
of mice with DSS-induced colitis. It is worth noting that
hydrocotarnine can signiﬁcantly attenuate weight loss,
extent of colon shortening, and the histopathology score
reﬂecting the protective effect of hydrocotarnine in DSSinduced colitis. Hydrocotarnine has been used clinically to
enhance analgesic effects of oxycodone for the relief of
pain and dyspnea in the patient with terminally ill cancer55,56, although the mechanism of action is mostly
unknown57. Our data therefore suggest that the manipulation of Cbl with hydrocotarnine to enhance NLRP3
inﬂammasome activation could be relevant for the treatment of infectious disease, colitis, and cancer.
In summary, we herein propose a model for the previously unrecognized SFK-Cbl axis-dependent suppression of NLRP3 inﬂammasome activation. We show that
SFK-Cbl activity increases the threshold for NLRP3
inﬂammasome activation by maintaining Pyk2 signaling
and mtROS at appropriately low levels. Our ﬁndings
suggest that Cbl should be considered as a new
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therapeutic target of hydrocotarnine in the treatment of
inﬂammation-related diseases related to NLRP3 inﬂammasome activation.
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